Compare Adaptive Biotechnologies Corp (ADPT) vs Amer Sports Inc (AS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Amer Sports Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while Amer Sports Inc trades at $33.87 (market cap $21.04B). The key difference: Amer Sports Inc is far larger — about 5.2× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Amer Sports Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | AS | |
|---|---|---|
Market Cap | $4.05B | $21.04B |
Sector | Health | Technology |
52-Week High | $25.45 | $41.96 |
52-Week Low | $12.30 | $29.54 |
Enterprise Value | $4.12B | $21.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
Amer Sports (AS) trades at $36.84, up 2.02% today, with a bullish technical signal from moving averages and strong analyst consensus. The company reported robust Q1 2026 results, beating EPS estimates with $0.38 versus $0.31 expected, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion, driven by strength in Arc'teryx and Salomon brands.
Outlook is positive given earnings momentum and raised 2026 guidance, but risks include high valuation (P/E 45.2) and dependence on premium brand sustainability. The consensus price target of $58.67 implies significant upside, supported by 12 buy ratings. Investors should monitor Q2 2026 earnings on August 18 for continued growth validation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →
